Using a combination of pretreatment plasma and saliva can increase the sensitivity of pretreatment HPV-16 status as a tool for screening patients with HPV-16-positive OPSCC. In addition, analysis of HPV-16 DNA in saliva and plasma after primary treatment may allow for early detection of recurrence in patients with HPV-16-positive OPSCC.
No takes yet. Share an insight, caveat, or question.
Ahn et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: